M

    Molecular Partners AG ADR (MOLN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.28
    -0.22 (-4.89%)

    Market Cap: $172.37M

    Last updated: Aug 31, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    80%(16/20)
    Avg Surprise
    +93.38%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.35
    Range$-0.37 - $-0.34
    2 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.34+4.2%
    60d ago$-0.34+4.2%
    30d ago$-0.34+4.2%
    7d ago$-0.35+0.0%
    Current$-0.35
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Dec 31, 2026
    EPS Consensus$-0.13
    Range$-0.42 - $0.38
    3 analysts
    Revenue Consensus
    $6M
    Range$0 - $22M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.13---
    Sep 26EST
    		-$-0.35---
    Jun 26
    		$-0.44$-0.45+2.22%Beat+35.9%
    Mar 26
    		$-0.45$-0.41-8.15%Miss+10.6%
    Dec 25
    		$-0.36$-0.29-24.14%Miss-20.0%
    Sep 25
    		$-0.33$-0.37+10.81%Beat+32.7%
    Jun 25
    		$-0.69$-0.50-37.48%Miss-49.3%
    Mar 25
    		$-0.50$-0.37-35.14%Miss+16.7%
    Dec 24
    		$-0.30$-0.39+23.08%Beat+50.0%
    Sep 24
    		$-0.49$-0.54+9.26%Beat-24.3%
    Jun 24
    		$-0.46N/A+63.49%Beat+15.1%
    Mar 24
    		$-0.60$-1.00+40.00%Beat-22.3%
    Dec 23
    		$-0.60$-0.97+38.14%Beat-11.1%
    Sep 23
    		$-0.39$0.00N/AMiss+7.0%
    Jun 23
    		$-0.54$-0.87+37.74%Beat-111.8%
    Mar 23
    		$-0.49$0.00N/AMiss-110.6%
    Dec 22
    		$-0.54$-0.90+40.00%Beat+3.6%
    Sep 22
    		$-0.42$-0.66+35.39%Beat+29.5%
    Jun 22
    		$4.59$-0.66+799.80%Beat+836.6%
    Mar 22
    		$4.62$-0.66+804.38%Beat+847.9%
    Dec 21
    		$-0.56$-1.04+46.15%Beat+6.8%
    Sep 21
    		$-0.60$-0.60+0.00%Beat+20.8%
    Jun 21
    		$-0.62$-0.62+0.00%Beat+4.5%
    Mar 21
    		$-0.62$-0.79+21.96%Beat-11.7%
    Dec 20
    		$-0.60$0.00N/AMiss+6.2%
    Sep 20
    		$-0.76$0.00N/AMiss-34.1%
    Jun 20
    		$-0.65$0.00N/AMiss-18.9%
    Mar 20
    		$-0.55$0.00N/AMiss-80.6%
    Dec 19
    		$-0.64$0.00N/AMiss-113.5%
    Sep 19
    		$-0.57$0.00N/AMiss+6.8%
    Jun 19
    		$-0.55$0.00N/AMiss+9.7%
    Mar 19
    		$-0.31$0.00N/AMiss-8.1%
    Dec 18
    		$-0.30$0.00N/AMiss-3.2%
    Sep 18
    		$-0.61$0.00N/AMiss-309.4%
    Jun 18
    		$-0.61$0.00N/AMiss-307.6%
    Mar 18
    		$-0.28$0.00N/AMiss+51.6%
    Dec 17
    		$-0.29$0.00N/AMiss+21.3%
    Sep 17
    		$-0.15$0.00N/AMiss+17.3%
    Jun 17
    		$-0.15$0.00N/AMiss-
    Mar 17
    		$-0.59$0.00N/AMiss-
    Dec 16
    		$-0.37$0.00N/AMiss-
    Sep 16
    		$-0.18$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-2.71EV/EBITDA1.24x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-62.00%ROIC-86.72%
    Financial Health
    Debt/Equity0.02xInterest CoverageN/A
    Current Ratio7.27xQuick Ratio7.27x
    Trading Statistics
    Beta0.68Avg Volume1.43K
    52-Week High$5.3652-Week Low$3.53

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.39
    SMA 20$4.27
    SMA 50$4.09
    SMA 200$4.24
    EMA 10$4.38
    EMA 20$4.29
    EMA 50$4.16
    EMA 200$4.15

    MACD

    Line: 0.11Signal: 0.10Hist: 0.01

    ADX

    ADX: 9.2+DI: 34.7-DI: 42.4

    Aroon & PSAR

    Aroon Up96.0
    Aroon Down4.0
    PSAR$4.24

    Bollinger Bands

    Upper Band$4.58
    Lower Band$3.95
    %B Position1474%(Upper)
    Band Width0.52

    RSI (14-Day)

    Neutral
    51.6

    Momentum Oscillators

    Stoch %K66.7
    Stoch %D82.9
    Williams %R-69.6
    ROC (10d)0.7%
    Momentum0.03
    CCI (20d)38.8
    MFI (14d)52.6

    Volatility Measures

    ATR (14d)$0.12(2.9%)
    StdDev (20d)0.16
    Hist Vol35.8%(Moderate)

    Volume Flow

    VWAP$4.34
    OBV353.0K
    AD Line33.7K
    CMF (20d)0.254

    Volume Metrics

    Avg Vol (20d)1.2K
    Vol Ratio0.3x(Low)
    VWMA (20d)$4.38

    Pivot Points

    R3$4.78
    R2$4.73
    R1$4.61
    Pivot Point$4.56
    S1$4.44
    S2$4.39
    S3$4.27

    Advanced Oscillators

    TSI22.33
    Ultimate Osc64.2
    KST89.30

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$0$0$681,000$1.55M$2.74M$1.03M$2.54M
    Cost of Revenue$492,213$9.45M$641,873$658,569$668,784$614,034$9.45M$10.86M$13.09M$14.10M$11.91M$11.61M
    Gross Profit$-492,213$-9,445,000$-641,873$-658,569$-668,784$-614,034$-9,449,000$-10,183,000$-11,536,000$-11,366,000$-10,878,000$-9,066,000
    Operating Expenses$13.79M$4.00M$15.21M$14.25M$17.32M$17.34M$5.34M$4.41M$4.44M$4.49M$5.77M$16.03M
    R&D$0$9.45M$11.56M$10.41M$10.71M$13.26M$10.55M$10.86M$13.09M$14.10M$12.85M$11.61M
    SG&A$0$4.00M$3.06M$3.60M$3.99M$4.22M$3.83M$4.41M$4.44M$4.49M$4.46M$4.42M
    Operating Income$-13,787,062$-13,443,000$-15,847,890$-14,908,425$-17,317,000$-17,956,045$-14,794,000$-14,589,000$-15,976,000$-15,858,000$-16,648,000$-13,489,000
    Interest Income$0$176,000$234,000$366,000$420,000$502,000$651,000$718,000$912,000$1.10M$1.13M$1.19M
    Interest Expense$11,186$7,000$13,763$0$4,000$10,011$6,000$9,000$6,000$7,000$11,000$8,000
    Income Before Tax$-13,786,045$-13,144,000$-15,821,615$-14,790,957$-20,398,000$-18,656,844$-11,230,000$-16,404,000$-15,082,000$-11,325,000$-19,780,000$-11,439,000
    Income Tax Expense$0$0$0$0$0$0$2,000$0$0$561,724$558,188$8,000
    Net Income$-13,786,045$-13,144,000$-15,826,620$-14,790,957$-20,398,000$-18,655,732$-11,232,000$-16,404,000$-15,082,000$-11,325,000$-19,780,000$-11,439,000
    EBITDA$-13,787,062$-12,636,000$-15,206,017$-14,249,856$-19,841,000$-17,342,011$-10,654,000$-15,804,000$-14,470,000$-10,710,000$-19,167,000$-10,824,000
    EBIT$-14,279,275$-13,137,000$-15,847,890$-14,908,425$-20,394,000$-17,956,045$-11,224,000$-16,395,000$-15,073,000$-11,315,000$-19,769,000$-11,428,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MOLN

    News

    Molecular Partners (NASDAQ:MOLN): Why Is Today's Company Update a Key Execution Test?

    Molecular Partners (NASDAQ:MOLN) is releasing its quarterly update today, prompting an assessment of its position within the Penny Stocks category. This event will highlight key operational aspects such as clinical evidence, program prioritization, collaboration economics, regulatory work, manufacturing, and cash utilization. The article emphasizes that this update serves as a critical test of the company's execution, distinguishing established operating trends from future-dependent narratives for this clinical-stage biotechnology firm.

    Kalkine Media•8/25/26•
    Neutral

    Molecular Partners AG reports results for the quarter ended June 30 - Earnings Summary

    Molecular Partners AG has released its earnings summary for the quarter that ended on June 30. The full article containing these results is available for review. Readers can access this and other news sources through a TradingView subscription.

    TradingView•8/25/26•
    Neutral

    Molecular Partners H1FY26 Results: Net loss narrows to CHF 26.7m

    Molecular Partners AG reported a net loss of CHF 26.7 million for H1 2026, a significant improvement from CHF 37.2 million in H1 2025, driven by cost management and clinical pipeline progress. The company's cash position stands at CHF 67.9 million, sufficient to fund operations into late 2027. Its lead candidate MP0712 has advanced to dose level 2 in its Phase 1/2a study, with initial clinical data expected later in 2026.

    scanx.trade•8/25/26•
    Bullish

    Molecular Partners (NASDAQ: MOLN) sees cash last into 2027 despite H1 2026 loss

    Molecular Partners (MOLN) reported its H1 2026 financial results, showing a narrowed net loss of CHF 26.7 million and total operating expenses of CHF 27.0 million. The company's cash and cash equivalents stood at CHF 67.9 million as of June 30, 2026, which is projected to fund operations into late 2027. Key clinical progress includes the advancement of its lead Radio-DARPin candidate, MP0712, to a higher dose level in a Phase 1/2a study for small cell lung cancer, and the selection of CD70 as a new radio target for kidney cancer.

    Stock Titan•8/25/26•
    Somewhat-Bullish

    Molecular Partners advances DLL3-targeting MP0712 in Phase 1/2a trial, selects CD70 for next radio-DARPin program, reports cash runway into late 2027

    Molecular Partners announced progress in its Phase 1/2a trial for MP0712, a DLL3-targeting Radio-DARPin for small cell lung cancer, which is now recruiting at the second dose level. The company has also selected CD70 as a new target for future radio-targeted therapies, with clinical trials expected to start in 2027. Molecular Partners reported a cash position of CHF 67.9 million as of June 30, 2026, projected to fund operations into late 2027, despite an operating loss of CHF 27.0 million in H1 2026.

    Quiver Quantitative•8/25/26•
    Somewhat-Bullish

    Frequently Asked Questions About MOLN

    Does MOLN pay dividends?
    Molecular Partners AG ADR (MOLN) does not currently pay a regular dividend.
    What is MOLN's market cap?
    Molecular Partners AG ADR (MOLN) has a market capitalization of $172.37M with a current stock price of $4.28.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In